JemsDevelopment of Anticancer Agents for Drug – Resistant Cancers (DAADRAC)
Priority Axis 1: Cooperating for smarter programme area
Operation start date: 1 July 2024
Operation completion date: 31 December 2025
Budget: EUR 306.892,00
Number of partners: 2
Operation purpose and expected achievements:
The overall project objective is the development of novel anticancer drugs, specifically tailored to combat drug-resistant cancers and to elevate the research capacities of two partneer institutions and to empower them to tackle this formidable healthcare challenge. The main achievements of the project will be:
– Enhancement of research and innovation capacities in the field of anticancer drug development
– Jointly Developed Solution for Drug-Resistant Cancer Combat as the identification of a refined anticancer lead compound addressing drug-resistant cancers
– Jointly Developed Pilot Action for Enhanced Anticancer Compound Testing that involves testing and optimizing anticancer compounds against drug-resistant cancer cells, encompassing experimental protocols for compound refinement and biological testing
– Solution based on the lead compound will be developed to modify activity and optimize pharmacokinetic properties.
Beneficiaries:
Faculty of Sciences, University of Novi Sad (RS) as Lead Partner will lead and conduct the Medicinal Chemistry Training for the Faculty of dental medicine and health Osijek team. This training aims to transfer essential knowledge in drug design and organic synthesis, enriching the expertise of our partners. Faculty of Sciences, University of Novi Sad will be responsible for the selection, synthesis, and preparation of anticancer compounds, which includes both the creation of new compounds and the purification to ensure their suitability for biological testing. Lead partner will undertake the analysis of raw research data generated during the project, which involves interpreting the results obtained from biological testing and chemical analysis, contributing to a comprehensive understanding of the project’s findings. Faculty of Sciences, University of Novi Sad will also take a lead role in disseminating the project’s results, which includes publishing research findings in peer-reviewed journals, sharing outcomes with the scientific community, students, and the general population, thereby contributing to the broader knowledge base in anticancer research.
Faculty of dental medicine and health Osijek (HR) as Project Partner will contribute with their different expertise in the field of growing cell lines and the methodological implementation of different analyses. The Laboratory team is multidisciplinary and includes associates who are doctors, and masters in biology, and chemistry. This multidisciplinary approach enables the implementation of translational research “from bench to bed side”, and significantly helps in achieving the Project’s goal. Using the acquired competencies in growing tumor cell lines, and experience in the methodology that supports previously mentioned analyzes of signaling pathways (such as MTS, RT-PCR, ELISA), the collaborators will significantly advance the understanding of the possible antitumor effect of selected compounds.